Pfizer, Allergan End $160B Merger After New Inversion Regs
Pfizer and Allergan called off their planned $160 billion combination Wednesday, marking an end to what would have been the largest so-called inversion transaction on record after the U.S. Department of...To view the full article, register now.
Already a subscriber? Click here to view full article